FormFactor

FORM

Market cap $8.23B

FORM's AI-driven HBM momentum, broader chip-testing wins and CPO growth support its outlook despite premium valuation and margin pressure.

LIVERMORE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) will report financial results for its 2026 fiscal second quarter on Wednesday, July 29th, 2026, at 1:25 p.m. Pacific Time. The public is invited to listen to a live webcast of FormFactor's conference call on the Investors section of the company's web site at www.formfactor.com .

FORM's AI infrastructure push is fueling demand for probe cards, HBM testing, GPUs, custom ASICs and CPO, with revenue gains eyed through 2030.

Micron, FormFactor, Texas Instruments and Taiwan Semiconductor are positioned to benefit as AI capex fuels demand for chips, memory and testing.

LIVERMORE, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) announced today that it was added as a member of the US large-cap Russell 1000® Index, effective when the US market opens on June 29th, as part of the 2026 Russell indexes reconstitution. Membership in the Russell 1000® Index, which remains in place for half a year beginning 2026, is based on membership in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes.

FormFactor (FORM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Investors need to pay close attention to FORM stock based on the movements in the options market lately.

FormFactor (FORM) reported earnings 30 days ago. What's next for the stock?

FormFactor (FORM) dropped 12.8% after unveiling an ambitious 2030 plan targeting $1.6B revenue, 55% gross margin, and $5.00 non-GAAP EPS. FORM's forward thesis centers on HBM4 share gains, GPU and co-packaged optics catalysts, and a Texas plant expansion unlocking probe-card capacity. Valuation remains stretched at 12.06x forward sales, with execution risk tied to Texas plant readiness and potential earnings misses impacting 2027 guidance.